![]() |
|
|
Vol. 26, Issue 6, 566-571, June 1998
Developmental Research Laboratories, Dainippon Pharmaceutical Co.,
Ltd. (T.H., M.M., Y.T., T.F., H.M.), and the
Department of
Pharmacology, University of Toronto (L.O., T.I.)
Ebastine
[4'-tert-butyl-4-[4-(diphenylmethoxy)piperidino]butyro phe- none]
is a new-generation, nonsedative, H1
antihistamine. The present study was performed to characterize the
cytochrome P450 (CYP) isoforms responsible for ebastine
N-dealkylation and hydroxylation. Human liver microsomes
metabolized ebastine to two major metabolites, i.e. a
desbutyrophenone metabolite (des-BP) and hydroxyebastine (M-OH), and
the ratio of Vmax values was 3:1. N-Dealkylation yielded des-BP, whereas M-OH, an
hydroxylation product, could be further oxidized to the
pharmacologically active carebastine. In a panel of 14 human liver
microsomal preparations, the rate of dealkylation showed a highly
significant correlation with CYP3A-mediated testosterone
6
-hydroxylation but not with reactions of seven other CYP isoforms.
However, there was no correlation between the two pathways for ebastine
(dealkylation and hydroxylation). Differential chemical inhibition in
liver microsomes, in which dealkylation was more sensitive than
hydroxylation, was demonstrated with ketoconazole, troleandomycin,
cyclosporin A, and midazolam. Anti-CYP3A antibodies markedly reduced
the dealkylation rate (>95%) in liver microsomes but exhibited
insignificant effects on hydroxylation (<5%). Among 12 cDNA-expressed
human CYP isoforms, which account for up to 70% of the total CYP
enzyme content in human liver, CYP3A4 alone metabolized ebastine; the
ratio of des-BP to M-OH formation was 12:1. This ratio for metabolism
by the pure enzyme was much larger than the ratio (3:1) observed for
the microsomal reaction mixture. This change in ratio, which is
attributed to a decrease in M-OH formation, indicates that, although
ebastine is metabolized to two major metabolites,
N-dealkylation to des-BP is mediated by CYP3A, whereas
hydroxylation to M-OH appears to be mediated mainly by unidentified
enzymes other than CYP3A.
This article has been cited by other articles:
![]() |
K.-H. Liu, M.-G. Kim, D.-J. Lee, Y.-J. Yoon, M.-J. Kim, J.-H. Shon, C. S. Choi, Y. K. Choi, Z. Desta, and J.-G. Shin Characterization of Ebastine, Hydroxyebastine, and Carebastine Metabolism by Human Liver Microsomes and Expressed Cytochrome P450 Enzymes: Major Roles for CYP2J2 and CYP3A Drug Metab. Dispos., November 1, 2006; 34(11): 1793 - 1797. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Matsumoto, T. Hirama, T. Matsubara, K. Nagata, and Y. Yamazoe Involvement of CYP2J2 on the Intestinal First-Pass Metabolism of Antihistamine Drug, Astemizole Drug Metab. Dispos., November 1, 2002; 30(11): 1240 - 1245. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hashizume, S. Imaoka, M. Mise, Y. Terauchi, T. Fujii, H. Miyazaki, T. Kamataki, and Y. Funae Involvement of CYP2J2 and CYP4F12 in the Metabolism of Ebastine in Human Intestinal Microsomes J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 298 - 304. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hashizume, M. Mise, S. Matsumoto, Y. Terauchi, T. Fujii, S. Imaoka, Y. Funae, T. Kamataki, and H. Miyazaki A Novel Cytochrome P450 Enzyme Responsible for the Metabolism of Ebastine in Monkey Small Intestine Drug Metab. Dispos., June 1, 2001; 29(6): 798 - 805. [Abstract] [Full Text] |
||||